APR 30, 2016 9:45 AM PDT

Short-Term Leukemia Success Attributed to Immunotherapy

WRITTEN BY: Xuan Pham
Immunotherapy led to remission in 93 percent of leukemia patients
Researchers recently reported that immunotherapy led to remission in 93 percent of patients with advanced leukemia. Though these ‘extraordinary’ results have only been evaluated in the short-term, the technique devised in this study has the potential to improve current and future immunotherapy treatments.
 
Immunotherapy is a type of cancer treatment that stimulates the body’s natural defenses to kill cancer cells. In some forms of immunotherapy, scientists harvest the patient’s immune T-cells and genetically alter them to carry a synthetic receptor molecule called a CAR (for chimeric antigen receptor). These specialized CAR-T cells are then able to recognize and destroy cancer cells that have a specific marker, known as CD19.
 
 

Though this technique has been shown to be powerful against cancer, the factors that determine the efficacy and toxicity of such treatment has been hard to study. To better understand how immunotherapy works and to improve on it, a team of researchers administered a defined mixture of CAR-engineered helper and killer T cells to patients with acute lymphoblastic leukemia (ALL). This is the first immunotherapy trial to use an even composition of the two T-cell types in patients.
 
Of the 29 leukemia patients who received the CAR-T cell mixture, 27 (93 percent) showed remission, with a total absence of cancer cells in their bone marrow. In addition of the 2 patients who did not experience remission, one patient was given a higher dose of the engineered cells and subsequently achieved remission.
 
"Patients who come onto the trial have really limited options for treatment. They have refractory, acute leukemia. So the fact that we're getting so many into remission is giving these people a way forward," said study leader Dr. Cameron Turtle.
 
But as extraordinary as the results appear, it is too early to conclude long-term victories with this treatment. The high percentage of remission was not sustained, as some patients relapsed even after traces of the cancer were seemingly gone. Two patients also relapsed with highly resistant leukemias that were immune to the CAR-T cells.
 
"This is just the beginning," Turtle said. "It sounds fantastic to say that we get over 90 percent remissions, but there's so much more work to do make sure they're durable remissions, to work out who's going to benefit the most, and extend this work to other diseases."
 
"In early-phase trials, you're continually learning. You don't expect results like these from early-phase trials. That's why these response rates are so extraordinary," said David Maloney, senior study author.

Additonal source: Fred Hutchinson Cancer Research Center
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 30, 2020
Cancer
Fighting mesothelioma with curcumin
OCT 30, 2020
Fighting mesothelioma with curcumin
Research led by investigators at Flinders University in Australia is spearheading new developments in cancer prevention ...
NOV 24, 2020
Cancer
Using Restfulness as a Metric for Measuring Sleep Quality and Cardiovascular Risk
NOV 24, 2020
Using Restfulness as a Metric for Measuring Sleep Quality and Cardiovascular Risk
Did you know sleeping is great? Apparently, getting a full eight hours every night can make you look fabulous and solve ...
DEC 21, 2020
Cancer
Cancer survivors have a higher risk of developing subsequent primary cancers
DEC 21, 2020
Cancer survivors have a higher risk of developing subsequent primary cancers
New research published in JAMA has found that cancer survivors have a higher risk of developing subsequent primary cance ...
DEC 25, 2020
Immunology
A High-Fat Diet Starves Immune Cells, Tumor Growth Goes Unchecked
DEC 25, 2020
A High-Fat Diet Starves Immune Cells, Tumor Growth Goes Unchecked
  Sitting down to enjoy an indulgent Christmas feast? A recent study in mice by Harvard Medicine scientists found t ...
JAN 02, 2021
Cancer
Mothers and fathers take the financial toll of having a child with cancer differently
JAN 02, 2021
Mothers and fathers take the financial toll of having a child with cancer differently
A new study by researchers at Uppsala University in Sweden contemplates the socioeconomic impact on parents of having a ...
JAN 04, 2021
Cancer
The most diverse genetic analysis of prostate cancer to date
JAN 04, 2021
The most diverse genetic analysis of prostate cancer to date
Racial health disparities are glaringly obvious in the case of prostate cancer where the risk level is roughly 75% highe ...
Loading Comments...